NCT04712643Active, not recruitingPhase 3
A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma
A Phase III, Open-Label, Randomized Study of On-Demand TACE Combined With Atezolizumab Plus Bevacizumab (Atezo/Bev) or On-Demand TACE Alone in Patients With Untreated Heaptocellular Carcionma
Source: ClinicalTrials.gov · Last updated 26 Oct 2026
Brief summary (registry, in English)
This study will evaluate the efficacy and safety of atezolizumab plus bevacizumab combined with on-demand TACE compared to on-demand TACE alone in participants with hepatocellular carcinoma who are at high risk of poorer outcome following TACE treatment.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 342 (actual)
- First submitted
- 14 Jan 2021
- Start date
- 12 Mar 2021
- Primary completion date
- 1 Feb 2029
- Lead sponsor
- Hoffmann-La Roche
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT04712643
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 342
- From 12 Mar 2021 to the primary completion date, 1 Feb 2029
- 40 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- A prior bleeding event due to esophageal and/or gastric varices within 6 months prior to initiation of study treatment
Other illness
- Any condition representing a contraindication to TACE as determined by the investigators
- Active or history of autoimmune disease or immune deficiency
- Untreated or incompletely treated esophageal and/or gastric varices with bleeding or high risk for bleeding
- Evidence of bleeding diathesis or significant coagulopathy
Other
- Evidence of Vp3/4 and hepatic vein tumor thrombus (HVTT)
- Evidence of extrahepatic spread (EHS)
- Being a candidate for curative treatments
Who the study is looking for
- Confirmed diagnosis of HCC by histology/ cytology or clinical criteria
- Eligible for TACE treatment
- No prior systemic therapy for HCC, especially immunotherapy
- No prior locoregional therapy to the target lesion(s)
- At least one measurable untreated lesion
- ECOG Performance Status of 0-1
- Child-Pugh class A
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (40)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Anhui Provincial Hospital Coordinator of this site? Confirm its status | Anhui | China | Unknown status |
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Beijing You An Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Beijing Tsinghua Changgung Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| Hunan Cancer Hospital Coordinator of this site? Confirm its status | Changsha | China | Unknown status |
| West China Hospital，Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| The First Affiliated Hospital, Chongqing Medical University Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
| Southwest Hospital , Third Military Medical University Coordinator of this site? Confirm its status | Chongqing | China | Unknown status |
| Fujian Cancer Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
| The First Affiliated Hospital of Fujian Medical University Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
| Mengchao Hepatobiliary Hospital of Fujian Medical University Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
| The 900th Hospital of PLA joint service support force Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
| Nanfang Hospital, Southern Medical University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Sun Yet-Sen University Cancer Center Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Zhejiang Cancer Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| Harbin Medical University Cancer Hospital Coordinator of this site? Confirm its status | Harbin | China | Unknown status |
| Jiangsu Province Hospital (the First Affiliated Hospital With Nanjing Medical University) Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
| Jiangsu Cancer Hospital Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
| The First Affiliate Hospital of Guangxi Medical University Coordinator of this site? Confirm its status | Nanning | China | Unknown status |
| Guangxi Cancer Hospital of Guangxi Medical University Coordinator of this site? Confirm its status | Nanning | China | Unknown status |
| Zhongshan Hospital Fudan Unvierstiy Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Fudan University Shanghai Cancer Center Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Renji Hospital, Shanghai Jiaotong University School of Medicine Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Shengjing Hospital Of China Medical University Coordinator of this site? Confirm its status | Shenyang | China | Unknown status |
| Tianjin Cancer Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
| Xi'an Inernational Medical Center Hospital Coordinator of this site? Confirm its status | Xi'an | China | Unknown status |
| The First Affiliated Hospital of Xi'an Jiaotong University Coordinator of this site? Confirm its status | Xi’an | China | Unknown status |
| Henan Cancer Hospital Coordinator of this site? Confirm its status | Zhengzhou | China | Unknown status |
| Zhuhai People's Hospital Coordinator of this site? Confirm its status | Zhuhai | China | Unknown status |
| Aichi Cancer Center Coordinator of this site? Confirm its status | Aichi | Japan | Unknown status |
| Chiba University Hospital Coordinator of this site? Confirm its status | Chiba | Japan | Unknown status |
| Kurume University Hospital Coordinator of this site? Confirm its status | Fukuoka | Japan | Unknown status |
| Hiroshima University Hospital Coordinator of this site? Confirm its status | Hiroshima | Japan | Unknown status |
| Yokohama City University Medical Center Coordinator of this site? Confirm its status | Kanagawa | Japan | Unknown status |
| Kitasato University hospital Coordinator of this site? Confirm its status | Kanagawa | Japan | Unknown status |
| Kanagawa Cancer Center Coordinator of this site? Confirm its status | Kanagawa | Japan | Unknown status |
| The University of Osaka Hospital Coordinator of this site? Confirm its status | Osaka | Japan | Unknown status |
| Kindai University Hospital Coordinator of this site? Confirm its status | Osaka | Japan | Unknown status |
| Toranomon Hospital Coordinator of this site? Confirm its status | Tokyo | Japan | Unknown status |
Related publications
- On-demand transarterial chemoembolisation combined with atezolizumab and bevacizumab in patients with untreated hepatocellular carcinoma (TALENTACE): a multicentre, randomised, open-label, phase 3 trial.Lancet Gastroenterol Hepatol · 2026 · PMID 42641632
This page is information, not medical advice. Discuss any trial with your doctor.